Thursday, August 31, 2017 1:51:58 AM
I suppose you have possibly read my newest article on SA?
Agreed that they have everything here that they need to make a formidable company; Baxdela and solithromycin have a lot of potential.
Baxdela is the only fluoroquinolone to be approved for ABSSSI -- as far as I know. And fluoroquinolones (FQs) are known for two things:
(1) Tendon rupture. 2014: 21 confirmed cases of "FQ-associated disability" (https://en.wikipedia.org/wiki/Fluoroquinolone-associated_disability) out of 32.8m oral FQ prescriptions. That's pretty rare, though. But most also have QT prolongation, which Baxdela doesn't have. And it is very different from many other FQs.... so who knows.
(2) Their extreme potency. Baxdela is especially potent here in methicillin resistant Staphulococcus aureus, which is a big thing:
.MT @jcederholm: Prevalence of #AMR in the @WHO European Region #MRSA #AntibioticResistance @WHO_Europe pic.twitter.com/f76H7oWLGc
— Melinta Therapeutics (@MelintaTx) July 14, 2015
And then there is Taksta (old but will generate revenue since not available in US), radezolid, and oxazolidinone....
A lot of possibilities.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM